Skip to main content
Oncopeptides logo

Oncopeptides — Investor Relations & Filings

Ticker · ONCO ISIN · SE0009414576 LEI · 549300J9WWQ5CBYQ1M77 ST Manufacturing
Open in API
Filings indexed 489 across all filing types
Latest filing 2026-05-21 Declaration of Voting R…
Country SE Sweden
Listing ST ONCO

About Oncopeptides

https://www.oncopeptides.com/en

Oncopeptides is a biotechnology company focused on the research, development, and commercialization of targeted therapies for difficult-to-treat cancers. The company concentrates on hematological diseases, with a primary focus on multiple myeloma. Its commercialized product is Pepaxti (melflufen), a peptide-drug conjugate for adult patients with relapsed or refractory multiple myeloma. Founded in 2000 based on research from leading cancer institutions, Oncopeptides leverages its proprietary technology platforms to advance a pipeline of innovative drug candidates. The company's research also includes the development of Natural Killer (NK) cell engagers to address unmet medical needs in oncology.

Recent filings

Filing Released Lang Actions
Kommuniké från årsstämma i Oncopeptides
Declaration of Voting Results & Voting Rights Announcements Classification · 88% confidence The document is a press release titled “Kommuniké från årsstämma” (Communiqué from the Annual General Meeting) and enumerates all resolutions passed by shareholders at the AGM (election of board members, discharge from liability, approval of remuneration report, share programs, share issuance authorizations, etc.). This matches “Declaration of Voting Results & Voting Rights Announcements,” which covers official results from shareholder votes at general meetings. It is not the full annual report or an investor presentation but the formal outcome of the AGM votes.
2026-05-21 Swedish
Bulletin from the Annual General Meeting in Oncopeptides
Declaration of Voting Results & Voting Rights Announcements Classification · 91% confidence The document is a press release summarizing the principal resolutions passed at the Annual General Meeting, detailing the adoption of the annual report, director elections, remuneration approvals, incentive programs, and share issuance authorizations. This constitutes an official declaration of AGM voting results, rather than the full AGM materials or actual financial statements. It fits the definition of Declaration of Voting Results & Voting Rights Announcements (DVA).
2026-05-21 English
Interim / Quarterly Report 2026
Interim / Quarterly Report Classification · 91% confidence The document is titled “Delårsrapport Q1 2026” and contains actual interim financial statements (income statement, balance sheet, cash flow, summary of operations), a CEO’s letter, and detailed quarterly financial data for January–March 2026. It is not merely an announcement or attestation but a full interim/quarterly report. This matches the criteria for an Interim / Quarterly Report. Q1 2026
2026-05-13 Swedish
Interim / Quarterly Report 2026
Interim / Quarterly Report Classification · 95% confidence The document is titled “INTERIM REPORT Q1 2026” and contains full financial statements (income statement, balance sheet, cash flow, statement of changes in equity), a CEO statement, and period‐specific performance metrics for the quarter January–March 2026. It is not merely an announcement of a report but the actual quarterly report itself. This matches the definition of an Interim/Quarterly Report. Q1 2026
2026-05-13 English
Oncopeptides intends to submit type II variation to expand Pepaxti label to include third line treatment
Regulatory Filings Classification · 89% confidence The document is a corporate press release announcing the company’s intention to file a regulatory application (Type II variation) with the European Medicines Agency and providing investor webcast details. It does not contain actual financial statements or transaction details, nor is it a meeting agenda or voting result. It is a general regulatory announcement required under EU Market Abuse Regulation rather than an earnings, financial report, or proxy document. Therefore, it best fits the fallback category for general regulatory filings.
2026-05-11 English
Oncopeptides avser lämna in en typ II-variation för att expandera Pepaxtis indikation till behandling i tredje linjen
Regulatory Filings Classification · 72% confidence The document is a press release disclosing the company’s intention to file a Type II variation with the EMA to expand a drug indication and invites investors to a webcast. It contains no financial statements, no earnings data, no management or governance materials, and is not the actual regulatory report itself but a regulatory announcement under EU Market Abuse rules. It does not fit other specific categories and thus falls under the general regulatory announcement/fallback category.
2026-05-11 Swedish

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.